TWI911137B - 用於在手術前、中或後投與之glp-2類似物及肽體(peptibodies) - Google Patents

用於在手術前、中或後投與之glp-2類似物及肽體(peptibodies)

Info

Publication number
TWI911137B
TWI911137B TW107139266A TW107139266A TWI911137B TW I911137 B TWI911137 B TW I911137B TW 107139266 A TW107139266 A TW 107139266A TW 107139266 A TW107139266 A TW 107139266A TW I911137 B TWI911137 B TW I911137B
Authority
TW
Taiwan
Prior art keywords
glp
patient
surgery
peptide
bowel syndrome
Prior art date
Application number
TW107139266A
Other languages
English (en)
Chinese (zh)
Other versions
TW201922279A (zh
Inventor
科拉克 潘
安琪拉 諾頓
羅格 貝蒂娜 史塔克
克萊門 奧利佛
Original Assignee
日商武田藥品工業股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商武田藥品工業股份有限公司 filed Critical 日商武田藥品工業股份有限公司
Publication of TW201922279A publication Critical patent/TW201922279A/zh
Application granted granted Critical
Publication of TWI911137B publication Critical patent/TWI911137B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW107139266A 2017-11-06 2018-11-06 用於在手術前、中或後投與之glp-2類似物及肽體(peptibodies) TWI911137B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762582055P 2017-11-06 2017-11-06
US62/582,055 2017-11-06

Publications (2)

Publication Number Publication Date
TW201922279A TW201922279A (zh) 2019-06-16
TWI911137B true TWI911137B (zh) 2026-01-11

Family

ID=66332372

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107139266A TWI911137B (zh) 2017-11-06 2018-11-06 用於在手術前、中或後投與之glp-2類似物及肽體(peptibodies)

Country Status (14)

Country Link
US (1) US11660328B2 (cg-RX-API-DMAC7.html)
EP (1) EP3706774A4 (cg-RX-API-DMAC7.html)
JP (2) JP7296958B2 (cg-RX-API-DMAC7.html)
KR (1) KR102825098B1 (cg-RX-API-DMAC7.html)
CN (1) CN111629745A (cg-RX-API-DMAC7.html)
AR (1) AR113835A1 (cg-RX-API-DMAC7.html)
AU (1) AU2018360744A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020008936A2 (cg-RX-API-DMAC7.html)
CA (1) CA3079523A1 (cg-RX-API-DMAC7.html)
IL (1) IL274098B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020004620A (cg-RX-API-DMAC7.html)
TW (1) TWI911137B (cg-RX-API-DMAC7.html)
WO (1) WO2019090209A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202002080B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018321841A1 (en) * 2017-08-22 2020-02-20 Shire-Nps Pharmaceuticals, Inc. GLP-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions
WO2020086741A1 (en) * 2018-10-24 2020-04-30 Shire-Nps Pharmaceuticals, Inc. Glp-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions
SG11202111312UA (en) 2019-06-14 2021-12-30 Zealand Pharma As Pharmaceutical parenteral composition of dual glp1/2 agonist
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ,インク. Gpr119アゴニスト
MX2022010548A (es) 2020-02-28 2022-09-23 Kallyope Inc Agonistas de gpr40.
EP4126003A1 (en) * 2020-03-30 2023-02-08 Zealand Pharma A/S Glp-1/glp-2 dual agonists
MX2022014505A (es) 2020-05-19 2022-12-13 Kallyope Inc Activadores de la ampk.
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
WO2021263040A1 (en) * 2020-06-26 2021-12-30 Shire-Nps Pharmaceuticals, Inc. Stable peptibody formulations
CN115636876A (zh) * 2021-07-20 2023-01-24 重庆派金生物科技有限公司 胰高血糖素样肽-2突变体的定向化学偶联物及其应用
CN117467025B (zh) * 2023-12-28 2024-04-16 上海鼎新基因科技有限公司 一种抗vegf和补体双功能融合蛋白及其应用
WO2025181330A1 (en) * 2024-02-29 2025-09-04 Vectivbio Ag Dosage regimens for glucagon-like peptide 2 (glp-2) analogs

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006050244A2 (en) * 2004-11-01 2006-05-11 Nps Allelix Corp. Treatment of short bowel syndrome patients with colon-in-continuity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009510999A (ja) * 2005-07-29 2009-03-19 エーエムプロテイン コーポレイション キメラ治療剤
AU2006321743A1 (en) * 2005-10-24 2007-06-14 Centocor, Inc. GLP-2 mimetibodies, polypeptides, compositions, methods and uses
US7812121B2 (en) * 2006-08-31 2010-10-12 Baker Audrey E GLP-2 mimetibodies, polypeptides, compositions, methods and uses
JP2008247789A (ja) * 2007-03-30 2008-10-16 Kissei Pharmaceut Co Ltd クローン病に伴う腸管狭窄の進展抑制用医薬組成物
ES2687651T3 (es) * 2011-09-12 2018-10-26 Amunix Operating Inc. Composiciones de péptido-2 similar a glucagón y métodos para producir y usar los mismos
US9458214B2 (en) * 2011-09-26 2016-10-04 Novartis Ag Dual function fibroblast growth factor 21 proteins
KR101895047B1 (ko) * 2011-12-30 2018-09-06 한미사이언스 주식회사 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체
EA028929B1 (ru) 2012-05-03 2018-01-31 Зилэнд Фарма А/С Аналоги глюкагоноподобного пептида-2 (glp-2)
US10137170B2 (en) * 2013-12-20 2018-11-27 Indiana University Research And Technology Corporation Lipidated incretin receptor ligand human immunoglobulin Fc-region fusion polypeptides
KR101825048B1 (ko) 2014-12-31 2018-02-05 주식회사 제넥신 GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006050244A2 (en) * 2004-11-01 2006-05-11 Nps Allelix Corp. Treatment of short bowel syndrome patients with colon-in-continuity

Also Published As

Publication number Publication date
IL274098B1 (en) 2024-08-01
US20210169986A1 (en) 2021-06-10
AR113835A1 (es) 2020-06-17
EP3706774A4 (en) 2021-09-08
TW201922279A (zh) 2019-06-16
KR20200085763A (ko) 2020-07-15
MX2020004620A (es) 2020-10-12
JP7296958B2 (ja) 2023-06-23
CA3079523A1 (en) 2019-05-09
RU2020118172A (ru) 2021-12-08
KR102825098B1 (ko) 2025-06-26
AU2018360744A1 (en) 2020-05-07
JP7752152B2 (ja) 2025-10-09
CN111629745A (zh) 2020-09-04
IL274098B2 (en) 2024-12-01
JP2023107883A (ja) 2023-08-03
US11660328B2 (en) 2023-05-30
ZA202002080B (en) 2025-11-26
JP2021502389A (ja) 2021-01-28
WO2019090209A1 (en) 2019-05-09
BR112020008936A2 (pt) 2020-10-20
IL274098A (en) 2020-06-30
EP3706774A1 (en) 2020-09-16

Similar Documents

Publication Publication Date Title
JP7752152B2 (ja) 手術前、手術中または手術後に投与するためのglp-2類似体及びglp-2ペプチボディ
RU2606840C2 (ru) Композиция для лечения диабета, содержащая конъюгат инсулина длительного действия и конъюгат инсулинотропного пептида длительного действия
TWI816739B (zh) 包含調酸素及免疫球蛋白片段之蛋白質接合物的液態製劑
JP2019056013A (ja) ヒト成長ホルモン類似体を用いた小児成長ホルモン分泌不全症の治療
TW201625303A (zh) 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
EP3065765B1 (en) Use of il-22 dimers in manufacture of medicaments for treating pancreatitis
CN104144697A (zh) 利用免疫球蛋白片段的位点特异性glp-2缀合物
CN102389413A (zh) 用于治疗糖尿病的组合物及其应用
AU2015250039B2 (en) TRAIL receptor agonists for treatment of fibrotic diseases
JP5197012B2 (ja) 大腸連続性を伴う短腸症候群患者の治療
KR20150122136A (ko) 골격 성장 지연 질환의 예방 또는 치료에 사용하기 위한 용해성 섬유아세포 성장 인자 수용체 3(fgr3) 폴리펩티드
CN109328069B (zh) Il-22在治疗坏死性小肠结肠炎中的用途
HK40037000A (en) Glp-2 analogs and peptibodies for administration before during, or after surgery
WO2024141054A1 (zh) 包含融合蛋白的药物组合物及其用途
CA3008392C (en) Ameliorating systemic sclerosis with death receptor agonists
HK1258208B (en) Ameliorating systemic sclerosis with death receptor agonists